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Abstract
Rifampicin is currently recognized as the most potent drug against Gram positive implant related infections. The use of
rifampicin is limited by the emergence of bacterial resistance, which is often managed by coadministration of a second
antibiotic. The purpose of this study was to determine the effectiveness of soluble rifampicin in combination with
vancomycin tethered to titanium metal as a means to control bacterial growth and resistance in vitro. Bacterial growth was
inhibited when the vancomycin-tethered titanium discs were treated with Staphylococcus aureus inocula of #2610
6 CFU,
however inocula greater than 2610
6 CFU/disc adhered and survived. The combination of surface-tethered vancomycin with
soluble rifampicin enhanced the inhibitory effect of rifampicin for an inoculum of 10
6 CFU/cm
2 by one dilution (combination
MIC of 0.008 mg/L versus 0.015 mg/L for rifampicin alone). Moreover, surface tethered vancomycin prevented the
emergence of a rifampicin resistant population in an inoculum of 2610
8 CFU.
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Introduction
Infection is a persistent complication with a number of
implanted devices. In total joint replacement (TJR), implant
related infections are debilitating, costly and difficult to treat [1].
Patients with infected implants require prolonged hospitalization
and consume a disproportionate amount of healthcare resources
[1]. Improved operative techniques and short-term administration
of peri-operative antibiotics have proven successful in reducing the
overall incidence of prosthetic joint infection (PJI) (1.6% post-op
up to 2 years and 0.5% thereafter) [2]. However, PJIs persist and
are notoriously difficult to treat with systemic administration of
antibiotics.
The management of infected implants often necessitates a highly
invasive treatment plan [3,4] such as the two stage revision
procedure [5]. The first stage removes the infected implant and
surrounding tissue which is followed by six to twelve weeks of
antibiotic treatment. After antibiotic treatment, a second pro-
cedure is performed to reconstruct the joint with new implants [6].
A two stage procedure can be a long and costly process. One
strategy to potentially improve patient outcome and reduce the
burden of care, is a single stage revision [5,7]. In a single stage
procedure, the infected implant is removed, the wound is debrided
and cleaned and a new prosthesis is inserted, all during the same
surgical setting. Such single stage procedures were initially
performed with antibiotic-releasing bone cement but are now also
performed using cementless implants. Single stage procedures
have been shown to reduce the cost of PJI revision [8], however
concerns about the efficacy of treatment and the potential for the
recurrence of infection persist.
For TJRs performed without cement, titanium alloys are often
the preferred implant materials because of their biocompatibility
and elastic modulus [9]. The inherent biocompatibility of titanium
is attributed to a heterogeneous layer rich in oxygen that
spontaneously forms on the titanium surface. Strategies have been
developed to tether various molecules of biological interest such as
antibiotics to the titanium surface. Antibiotics such as ampicillin
[10], daptomycin [11] and vancomycin [12–16] maintain bio-
activity when covalently linked (tethered) to a solid surface. Several
techniques have been described for the covalent linkage to
a titanium oxide surface, where the organic-metal connection is
made through silane [17], phosphate [18], phosphonate [19] or
catechol [20] linkers. One strategy involving vancomycin is the
covalent bonding of the antibiotic to a titanium alloy surface
through a short polyethylene (PEG) tether using a silane linker
[14].
Vancomycin inhibits cell wall biosynthesis by binding to
terminal D-alanyl-D-alanine residues of NAG/NAM peptides,
preventing their cross-linking [21]. Surface bound vancomycin can
prevent biofilm formation on titanium surfaces in vitro, and in vivo
[22]. The tethering of vancomycin to the titanium surface is an
advantageous method of antibiotic prophylaxis since it precludes
exposure of the recipient’s flora to antimicrobial agents and the
need for intravenous delivery. Since vancomycin is active against
80% of microorganisms causing PJIs [23] it is also a relevant
choice for tethering to implant surfaces for the treatment of
infection.
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0The coadministration of vancomycin and rifampicin is the
mainstay in the treatment of methicillin-resistant Staphylococcus
aureus implant infection [24] and this combination is often used for
treatment durations exceeding six to twelve weeks. Rifampicin is
a drug of choice since it has excellent bioavailability, tissue
diffusion, can be administered orally once daily, and remains
active on biofilms [25]. Rifampicin is commonly coadministered
with other antibiotics since the emergence of resistant bacteria is
a common problem [26]. While vancomycin is an effective
antibiotic for the treatment of methicillin-resistant Staphylococcus
aureus, it has a poor tissue diffusion profile and can only be
administered intravenously with required serum level monitoring.
To ensure adequate bioavailability, administration of vancomycin
often precedes rifampicin and delays the beneficial effects of
rifampicin therapy.
To overcome these issues, the combination of implant-tethered
vancomycin with an oral regimen of rifampicin may be a practical
method to achieve an optimal antimicrobial environment imme-
diately following the implantation of a cementless implant for
revision surgery. In a clinical setting, intravenous vancomycin
could be coadministered to guard against resistance from
rifampicin monotherapy outside the joint space. The purpose of
this study was to determine if the combination of surface-tethered
vancomycin and soluble rifampicin would prevent the emergence
of resistance to rifampicin in S. aureus in vitro.
Materials and Methods
Bacterial strain and culture
All microbial studies were conducted using Staphylococcus aureus
ATCC strain 25923. Lyophilized stock was subcultured on Tryptic
Soy agar plates with 5% sheep blood (BD Diagnostics, Sparks,
MD) and a 10 ml preculture performed in Tryptic Soy Broth
(TSB) (DIFCO, BD Diagnostics). TSB (1 L) was seeded with the
preculture and grown to an optical density of 0.5 at 600 nm as
measured on a Nanodrop 2000c spectrophotometer (Thermo) and
then cooled on ice. The culture was pelleted and the pellet washed
with PBS (pH 7.2). Following a second centrifugation the pellet
was resuspended in PBS with 10% glycerol and 1 ml aliquots
frozen and stored at –80uC. Thawed aliquots were titrated by
plating serial dilutions on agar medium.
Preparation of Titanium Discs
Grade 5-ELI titanium alloy (TiAl6V4) discs (21 mm diameter
61 mm thickness) were fabricated in-house from rod stock. All
other materials were purchased from Sigma Aldrich (St. Louis,
MO) unless otherwise noted. Using standard metallurgical
techniques, the titanium discs were polished until they had
a mirror finish (Sa,0.02 mm). After polishing, discs were cleaned
for 30 minutes at 80uC in a 2% solution of Liquinox (White
Plains, NY) in an ultrasonic bath (Crest Ultrasonics, Tenton NJ).
Following cleaning, discs were passivated by treatment in 50%
nitric acid at 50uC with sonication for 1 h and then washed with
deionized H2O and dried in a 100uC oven. Discs were placed in
self-sealing sterilization pouches (Defend, Hauppauge NY) and
steam sterilized at 135uC for 20 minutes. At this point the
sterilized discs were split into 2 groups, control and experimental.
Tethering of vancomycin to titanium discs
The experimental titanium discs were identical to control discs
in every respect except that vancomycin was tethered to the disc
surface following the procedure of Jose et al. [14]. Briefly, the
tethering of vancomycin to the titanium surface was achieved as
follows: experimental discs were submerged in a sealed glass
chamber containing a solution of aminopropyltriethoxysilane
(1.2 ml, 5 mmol) in anhydrous toluene (50 ml) and heated to
120uC for 3 h. The discs were cooled, washed sequentially with
ethyl acetate, ethanol and deionized H2O, and dried under
vacuum. A short polyethylene glycol (PEG) based tether was then
linked to the exposed amino groups by treating the discs with 2-[2-
(fmoc-amino)ethoxy]ethoxyacetic acid (0.3 g, 0.8 mmol), COMU
(0.34 g, 0.8 mmol) and i-Pr2NEt (0.3 ml, 1.6 mmol) in dimethyl-
formamide (40 ml) for 1 h at 22uC. After washing (dimethylfor-
mamide), the fmoc group was removed by treatment with 25%
piperidine in dimethylformamide (50 ml), and the discs were
washed again (dimethylformamide and 2-propanol). The 2-[2-
(fmoc-amino)ethoxy]ethoxyacetic acid coupling and deprotection
protocol was repeated to double the length of the PEG linker. The
antibiotic was then covalently linked by treating the discs with
vancomycin hydrochloride (Hospira, Inc., Lake Forest, Il) (0.4 g,
0.27 mmol), COMU (0.12 g, 0.3 mmol) and i-Pr2NEt (0.4 ml,
2.2 mmol) in dimethylformamide (50 ml) for 16 h at 22uC. The
antibiotic-coupled discs were then washed (sequentially with
dimethylformamide, 2-propanol and deionized H2O) and dried
and stored under vacuum at ambient temperature until ready for
use.
Competitive Fluorescent Linked ImmunoSorbent Assay
(FLISA)
Control and experimental discs were placed in 12-well plates
(BD Falcon), blocked with 1% BSA in PBS (3 h at 37uC) and
washed with 0.05% PBS-Tween 20 (3615 min under orbital
agitation). Solutions of competing soluble vancomycin (0.25 ml, 0–
25 mg/well) were added to each well followed by 0.25 ml of
1:5,000 polyclonal rabbit anti-vancomycin antibody (Pierce
Thermo). After 45 min at 37uC, each well was washed
(360.05% PBS-Tween 20), treated with 0.5 ml 1:5000 Alexa
488-labeled goat anti-rabbit antibody (Invitrogen) and incubated
in the dark at 37uC for 45 min. The discs were washed (360.05%
PBS-Tween 20), and transferred to new plates with PBS (1 ml) in
each well. Fluorescence (excitation 488 nm, emission 525 nm) was
read on a Biotek H1 synergy plate reader (Biotek, Winooski, VT,
USA). All assays were performed in triplicate.
Resazurin biofilm assay and measurement of surface
antimicrobial activity
Control and experimental discs were placed in 12-well plates,
containing Mueller Hinton broth (MHB) (1 ml) and seeded with
ten-fold serial dilutions of thawed stock bacteria (2610
6 to 2610
3
CFU/well). The plates were centrifuged (10 min at 1000 G) and
incubated at 36uC for 18 h. The discs were washed gently to
remove unattached bacteria (36PBS) and transferred to a fresh
plate. Fresh MHB supplemented with 200 mM resazurin (Sigma)
(resazurin MHB) was added and incubated for 1 h. The
fluorescence of 100 ml aliquots of the resazurin MHB was then
measured (excitation 560 nm, emission 594 nm) to assess the
reduction of resazurin into the fluorescent resorufin compound,
a measure of metabolic activity of the disc-associated biofilm
[27,28]. All assays were performed in triplicate.
Synergy assay
A classic checkerboard synergy assay was performed according
to CLSI recommendations in resazurin MHB with an inoculum
of 5610
4 CFU/well under a final volume of 200 ml. The synergy
between vancomycin tethered to titanium and soluble rifampicin
was evaluated by inoculating control and experimental discs with
5610
6 CFU/well, then incubating with two-fold serial dilutions
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determined by comparing the lowest rifampicin concentration
capable of inhibiting growth on vancomycin treated surface to
the lowest concentration capable of inhibiting growth on a control
titanium surface. Inhibition of growth was determined by
colorimetric evaluation of the lack of resazurin reduction.
Confocal laser scanning microscopy of control and
experimental discs
Bacterial inocula suspended in MHB were added to control or
experimental discs placed in 12 well plates and centrifuged
10 minutes at 1000 G. Discs were gently washed three times in
PBS and stained with a live/dead BacLight bacterial viability kit
(Invitrogen) according to the manufacturer’s recommendations,
fixed in 4% paraformaldehyde containing PBS and imaged using
an upright Zeiss LSM 710 confocal microscope. Live bacteria
were stained with Syto9 (green) and dead bacteria stained with
both Syto9 and propidium iodide (yellow).
Statistical analysis
The significance of quantitative data was analyzed using
Student’s t test and a p value ,0.05 was considered to be
significant.
Results
Vancomycin tethered to the titanium surface can be
quantified by a competitive Fluorescent-Linked
ImmunoSorbent Assay
The amount of vancomycin tethered to the titanium surface was
determined using a competitive Fluorescent Linked ImmunoSor-
bent Assay. (Figure 1) Anti-vancomycin antibody was mixed with
varying amounts of soluble drug and then allowed to equilibrate
with the surface-tethered vancomycin. After washing and specif-
ically detecting vancomycin with a fluorescent secondary antibody,
the amount of vancomycin tethered to the disc surface was
established by determining the concentration of soluble competitor
that reduced the measured fluorescence by 50%. From this result
it was determined that 0.20 mg 60.06 of tethered vancomycin
(average from a duplicate assay of 3 batches) was attached per disk
face which also corresponded to 0.14 nmol or 8.3610
13
vancomycin molecules per disc face or one vancomycin molecule
per 3.8 nm
2.
The antimicrobial effect of vancomycin tethered to
titanium was inoculum dependent
Experimental discs inoculated with increasing amounts of S.
aureus were incubated overnight and the survival of metabolically
active bacteria adhering to the disc surface was measured using
resazurin reduction after thorough washing. Figure 2 shows
resorufin fluorescence according to the initial bacterial inoculum
used to seed the well. The distinction between measured
fluorescence on vancomycin-bound discs and control titanium
discs was large (.5-fold) for inocula of 2610
3,2 610
4 and 2610
5
CFU/disc (respective p values of 0.024, 0.047 and 0.022),
However, at the highest inoculation of 2610
6 CFU/disc,
fluorescence readings on the experimental discs approached levels
of the control disks (1.5 fold ratio, p=0.1), indicating that bacteria
survived on the antibiotic tethered surface.
The antimicrobial activity of soluble rifampicin was
additive to vancomycin tethered to titanium discs
A checkerboard experiment performed on control discs showed
that S. aureus ATCC 25923 had MICs of 0.5 mg/L to vancomycin
and 0.015 mg/L to rifampicin using the standard 5610
4 CFU
inoculum defined by CLSI. However, when applied in combina-
tion, sub-inhibitory concentrations of 0.25 mg/L of vancomycin
and 0.008 mg/L of rifampicin were sufficient to inhibit growth,
showing additivity of the two antibiotics. The possibility of
synergism between vancomycin tethered to the titanium surface
and soluble rifampicin was evaluated by determining the
concentration of rifampicin capable of inhibiting the growth of
S. aureus on experimental discs from an inoculum (5610
6 CFU)
high enough to overload the intrinsic antibacterial properties of
the vancomycin-tethered surface (Figure 2). A sub-inhibitory
concentration of 0.008 mg/L of rifampicin was found to be
sufficient to inhibit the growth on the experimental discs, whereas
0.015 mg/L rifampicin was required to inhibit the growth of
5610
6 CFU on control discs. Importantly, the MIC of rifampicin
was not modified by the 100-fold increase of inoculum. These
results show that like soluble vancomycin, titanium tethered
vancomycin was additive with soluble rifampicin.
Vancomycin tethered to titanium prevented the
emergence of resistance to rifampicin
The ability of surface-tethered vancomycin to prevent the
emergence of resistance to rifampicin was evaluated by measuring
the metabolic activity of adherent bacteria from increasingly dense
inoculations of S. aureus in the presence of 0.03 mg/L rifampicin
(Figure 3A). Control discs inoculated with 2610
6 and 2610
7 CFU
were sterile, as expected from their susceptibility to rifampicin.
Figure 1. Quantification of vancomycin covalently tethered to
the titanium surface. The amount of vancomycin tethered to the
titanium surface was determined using a competitive Fluorescent-
Linked ImmunoSorbent Assay. Anti-vancomycin antibody was mixed
with 5-fold dilutions of soluble vancomycin and then incubated with
the surface-tethered vancomycin. After washing and detecting with
a fluorescent secondary antibody, the amount of vancomycin bound to
the disc surface was calculated to be 0.20 mg [+/20.06] (average from
a duplicate assay of 3 batches [+/2 standard deviation]) or 0.14 nmol.
This corresponds to 8.3610
13 vancomycin molecules per disc face, or
one vancomycin molecule per 3.8 nm
2.
doi:10.1371/journal.pone.0052883.g001
Titanium-Tethered Vancomycin
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52883However, control discs inoculated with 2610
8 CFU were
colonized with live bacteria that were determined to be rifampicin
resistant with an MIC .4 mg/L. In contrast, vancomycin-
tethered discs and the overlying medium were sterile when
inoculated with 2610
8 CFU.
The surfaces of the discs inoculated with 2610
8 CFU were
observed by confocal laser scanning microscopy (CLSM) after
live/dead staining (Figure 3B). The vancomycin-tethered discs
were free of adhering bacteria (data not shown) whereas the
control discs were covered with a nascent biofilm populated with
a mixed population of live as well as dead bacteria incapable of
excluding propidium iodide. In the absence of the tethered
vancomycin, the rifampicin-resistant mutants were capable of
adhering to the surface and colonizing the medium and the disc
surface.
Discussion
Implant infection is a significant source of patient morbidity and
is predicted to impact future healthcare costs [29]. Antibiotic
resistance is persistent concern and revision surgery remains
a highly invasive procedure. There will always be a risk of infection
at the revision site since tissue spared to enable reconstruction may
harbor an inoculum. As a result, the development of new
approaches to treat implant related infections is of great interest.
In this study, it was demonstrated that vancomycin tethered to
titanium surfaces was effective for inhibiting the growth of S. aureus
and preventing the development of resistance to rifampicin in vitro.
Rifampicin is the preferred drug against methicillin-resistant
staphylococcal infection of implanted biomaterials, however, its
major drawback is the high frequency of rpoB mutants (range from
10
27 to 10
28) exhibiting resistance following exposure [30,31]. For
the treatment of PJIs, rifampicin is often coadministered with
another antibiotic agent due to the rapid emergence of bacterial
resistance. Despite combination therapy, there are instances of
selection of rifampicin resistant mutants due to the possible
different pharmacokinetic properties of the combination agents
[26,30,31]. Vancomycin is often co-administered with rifampicin,
but the systemic delivery of vancomycin is not without difficulty.
The pharmacokinetic/pharmacodynamic profile of vancomycin
does not ensure serum levels capable of preventing resistance to
rifampicin in the first days of therapy. As a result, it is common
practice to delay the administration of rifampicin to ensure
suitable levels of vancomycin are attained. This approach is
common since administration of rifampicin in the absence of
adequate levels of vancomycin could lead to a newly formed
biofilm on the revised implant that is populated with rifampicin-
resistant bacteria.
Vancomycin was selected for this study because it is used
clinically to treat periprosthetic joint infections in combination
with rifampicin [24]. Tethering vancomycin directly to the
implant surface solves the problem of its poor tissue distribution
relative to rifampicin, since it is present at an effective level ab initio.
Vancomycin is suitable for tethering because of its stability, its
amenability to covalent binding [15] and its mode of action.
Because vancomycin acts on the outer bacterial wall it can remain
tethered to the implant surface while interacting with biofilm
forming micro-organisms.
The antibacterial activity of vancomycin tethered to titanium
surfaces has been previously demonstrated [32], however the
mechanism of action is not completely understood. Soluble
vancomycin inhibits the cross-linking of D-Ala-D-Ala interpeptidic
bridges in the peptidoglycan all around the bacterial cell wall
whereas vancomycin tethered to titanium has limited cellular
contact. The quantity of tethered vancomycin required to inhibit
the activity of S. aureus is not understood either. In this study, the
coverage of one vancomycin molecule per 3.8 nm
2 is consistent
with the reported aminopropylsilanation of 0.22 nmol/cm
2 or 1
peptide per 0.8 nm
2 by Spencer et al. [17]. Approximating the
diameter of S. aureus as 1 mm, and that the titanium-tethered
vancomycin has a limited reach of ,5 nm from the metal surface,
the bacterial wall area exposed to antibiotic is less than
1.5610
4 nm
2, or 0.023% of the 6.5610
7 nm
2 surface area
(assuming a spherical cell and a compressible organic layer at
the bacterium-implant interface). Furthermore, a coverage of one
vancomycin molecule per 3.8 nm
2 would allow ,4000 molecules
to interact with the cell wall of a given bacterium. The results of
this study suggest that in vitro, 4000 vancomycin molecules or one
molecule per 3.8 nm
2 provide a sustained antibacterial effect.
This study determined that soluble rifampicin worked in
conjunction with surface-tethered vancomycin in vitro. The results
serve as an important proof of concept for more sophisticated
experiments which could address pharmacokinetic questions.
While promising, the effectiveness of this technique remains to
be evaluated in vivo where stability of the tethered antibiotic may
be an important issue. Silanization of the oxidized titanium surface
with aminopropyltriethoxysilane is a versatile method for co-
valently attaching organic molecules to oxides. The resulting
terminal amino group is amenable to further functionalization
using standard solid-phase organic synthesis techniques. Although
this silane-based chemistry is stable in vitro [33], concerns have
been raised about its stability under physiological conditions [19].
Figure 2. The antimicrobial effect of vancomycin tethered
titanium was inoculum dependent. Vancomycin tethered or
control discs were seeded with ten-fold dilutions of S. aureus stock
suspension and incubated overnight. The metabolically active bacteria
adhering to the disc surface were quantified by measuring resorufin
fluorescence. Vancomycin-tethered discs significantly inhibited the
adhesion and survival of 2610
3,2 610
4 and 2610
5 CFU compared to
control titanium discs (respective p values of 0.024, 0.047 and 0.022).
However at an inoculum 2610
6 CFU, the vancomycin-tethered discs
were not significantly different from controls.
doi:10.1371/journal.pone.0052883.g002
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have demonstrated the potential for this chemistry to be
sufficiently stable for use in medical devices. Furthermore, the
general strategy employed in our current study could readily be
adapted if necessary to potentially more robust phosphonate-based
linking chemistries [19]. Another area for optimization would be
to increase the access of the antibiotic to the bacterium. A flexible
linker connecting vancomycin to the aminopropylsilyl anchor was
used to allow the vancomycin molecule to adopt an effective
position. Longer linkers may be advantageous by allowing a greater
number antibiotic-bacteria interactions (vide supra), but may suffer
from lower yields in the chemical coupling reactions. In this study,
a previously validated aminoethoxyethoxyacetic acid dimer [14],
which has a length ,5 nm, was employed, but alternative linkers
are under current investigation.
The use of implant-tethered vancomycin may provide a prom-
ising adjunct for the immediate postoperative use of rifampicin in
the treatment of periprosthetic joint infections. The results of this
study suggest that further validation of this approach is warranted.
For example, the impact of the vancomycin tethering surface
treatments on osseointegration should be determined, and
evaluation in an animal model of PJI would provide additional,
valuable information. While this approach has been developed to
facilitate single stage revision for PJI, it could be applied to any
titanium implant vulnerable to infection, from external pin fixation
to dental implants or endovascular stents.
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